Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

April 05, 2022

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc.

Track this case

Case Number:

1:22-cv-00451

Court:

Delaware

Nature of Suit:

Patent - Abbreviated New Drug Application(ANDA)

Judge:

Richard G. Andrews

Firms

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. September 15, 2022

    Novartis Tells FDA Skinny Labels Won't Work With $3.5B Drug

    Novartis Pharmaceuticals has urged the U.S. Food and Drug Administration to reject generic versions of its blockbuster heart failure drug Entresto until its exclusivity expires in 2024, even if the generic-drug companies claim they can carve out protected uses. 

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login